Overall, our findings demonstrate that 4-OI modulates the basal activation of NLRP3 with gain-of-function variants in CAPS patients and thus inhibits basal puncta distribution of NLRP3, ASC oligomerization, caspase-1 activation, GSDMD processing and IL-18 release. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.